Advocacy intelligence hub — real-time data for patient organizations
Aarhus University Hospital
J-Pharma Co., Ltd. — PHASE3
Jazz Pharmaceuticals — PHASE3
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
RenJi Hospital
University of Southern California — PHASE1
Nexavar: FDA approved
Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Nexavar
Bayer HealthCare Pharmaceuticals, Inc.
Browse all Adenocarcinoma of the gallbladder and extrahepatic biliary tract news →
Hedy Kindler
University of Chicago Comprehensive Cancer Center
📍 CHICAGO, IL
Ghassan Abou-Alfa, MD, MD
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY
Tanios Bekaii-Saab, M.D
Ohio State University Comprehensive Cancer Center
📍 SCOTTSDALE, AZ
Anthony El-Khoueiry, M.D
SWOG Cancer Research Network
📍 LOS ANGELES, CA
Eric K Rowinsky, MD
Uniphar Development, LLC
📍 BOCA RATON, FL
Howard Safran, MD, M.D
BrUOG
📍 PROVIDENCE, RI
View all Adenocarcinoma of the gallbladder and extrahepatic biliary tract specialists →